gery was deferred. Twelve patients were diagnosed and treated prior to seeking weight-loss surgery, 2 patients were diagnosed intraoperatively and 8 patients postoperatively. Twenty-one pa- tients underwent LRYGB and one patient lap-band. Preoperative malignancies included: breast (n=4), leukemia/lymphoma (n=3), testicular (n=2), rectal (n=1), prostate (n=1), and lung (n=1). The mean patient age was 52.3 years (range: 30.6-68.5 years) and the median time interval between malignancy and surgery was 5 years (range 0.5-27 years). At a median follow-up time of 30.5 months all patients are alive and their %EWL is 66%.The two malignancies diagnosed during laparoscopy included a renal can- cer and a lymphoma presenting as mesenteric panniculitis. Post- operative malignancies included colorectal (n=2), leukemia/lym- phoma (n=2), renal (n=1), bladder (n=1), pancreatic (n=1), and duodenal GIST (n=1). These patients were diagnosed at a median time of 2.5 years postoperatively (range 0.5-5 years) and 2 patients have died secondary to their malignancy. Four patients underwent resection of their malignancy that was not limited by the previous bariatric operation. Conclusion: Prior history of treated malignancy is not a contra- indication for bariatric surgery in carefully selected patients. PII: S1550-7289(08)00377-8 PL-09. BARIATRIC SURGERY IMPROVES/PREVENTS CANCER IN MORBIDLY OBESE PATIENTS Nicolas V. Christou, MD PhD 1 ; John S. Sampalis, PhD 2 ; 1 Sur- gery, McGill University, Montreal, QC, Canada.; 2 JSS Re- search, Montreal, QC, Canada. Background: There is mounting evidence of an association be- tween obesity and cancer. Aim: In this study we examine the impact of bariatric surgery on cancer related comorbidity. Methods: Observational two-cohort study. The treatment cohort (n=1035) included patients having undergone bariatric surgery between 1986 and 2002. The control group (n=5746) included age and gender matched morbidly obese patients who had not under- gone weight-reduction surgery identified from a single payer ad- ministrative database. Subjects with physician/hospital visits for cancer related diagnosis/treatment for the previous 6 months at cohort-inception into the study were excluded. The cohorts were followed for a maximum of five years from inception. Results: Bariatric surgery resulted in significant reduction in mean percent excess weight loss (67.1%, p0.001). Surgery patients made significantly reduced physician/hospital visits for all cancer diagnoses. Common cancers such as breast were significantly reduced in the surgery group. All other cancers showed reduced clinical trends which were not statistically significant due to low frequencies. Conclusion: The data suggests that bariatric surgery improves and/or prevents development of cancer in morbidly obese patients. Diagnosis Bariatric surgery % No surgery control % Relative estimate Risk 95% CI p All Cancers 2.03 8.49 0.22 0.143 0.347 0.011 Breast 1.16 6.31 0.17 0.098 0.311 0.001 Colorectal 0.19 0.61 0.32 0.076 1.313 0.063 Pancreas 0.10 0.33 0.29 0.039 2.175 0.166 Endometrial 0.29 0.35 0.83 0.246 2.779 0.524 Kidney 0 0.1 NC NC NC 0.369 Myeloma 0 0.12 NC NC NC 0.313 Melanoma 0.19 0.47 0.41 0.097 1.723 0.158 Non Hodgkins Lymphoma 0.1 0.19 0.5 0.097 1.723 0.432 Others 0.1 0.15 0.4 0.065 3.091 0.412 PII: S1550-7289(08)00378-X PL-10. LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING: 2,176 PROCEDURES, WITH 12 YEARS FOLLOW-UP Jean-Marie Zimmermann, MD Ph; Michel Blanc; M. Imbert; Pierre Mashoyan; Jean-Marie Zimmermann, MD Ph; Surgery, Private Hospital CLAIRVAL, Marseille, France. Background: Authors present the results of 2,176 patients oper- ated by adjustable gastric banding in 12 years. Patients were screened, operated and followed up by the same surgical and multidisciplinary team in the same centre. Methods: Patients were operated from 1995 to 2007. Post-opera- tive consultations were performed each other month beginning at first month during the first year, twice a year thereafter. Surgical consultations included barium swallow, nutritional and behav- ioural follow-up. Results: In 2,176 patients (mean age 39.1 years, range16-68; 1,806F, 83%; 370M, 17%), with mean BMI 44.53 kg/m2 (range 36-78), mean weight 114.57kg and mean excess weight 46.77kg were implanted 2,210 bands. 29 were replaced (1.3%); 118 re- moved (5.4%), 100 converted into GBP (4.5%). 1,937 patients still have band in place (89%). EWL was 30%, 50.4%, 50.55%, 43%, 45.3 %, 42.94 %, 46.03 %, 40.47 % and 46.48 % at 6, 12, 24, 36, 48, 60, 72, 84 and 96 months respectively remaining stable at 45% until the twelfth year. Follow-up rate was: 99.9%, 88%, 85%, 83%, 80%, 75% and 70% at 1 month, 1 year, 2 years, 3 years, 5 years, 6 years and from seventh to twelfth year respectively. Complica- tions: 0 conversion; 3 trocars bleeding required laparoscopic re- intervention; 1 gastric perforation; 2 infections resulting in band removal; 2 deaths: a pulmonary embolism and a gastric necrosis; 245 slippages (11.2%): 200 perigastric (18.38%) and 45 pars- flaccida (4.1%); 32 erosions (1.44%). Conclusion: Laparoscopic adjustable gastric banding should be considered a satisfactory procedure with a good compromise be- tween risk and benefit. A cooperative patient optimise results. PII: S1550-7289(08)00379-1 PL-11. LONG-TERM RESULTS AFTER GASTRIC BANDING: 12 YEARS FOLLOW UP Philippe Mognol, MD; Konstantinos E. Arapis, MD, PhD; Hopi- tal BICHAT, Paris, France. 292 Abstracts: 2008 Plenary Session I / Surgery for Obesity and Related Diseases 4 (2008) 289 –311